This could also occur for the PD-1 and PD-L1 immunotherapies in melanoma ... Although effectiveness was shown in patients with a range of levels of HER2 staining, NICE limited reimbursement ...

Diagnosis of PDB is a combination of clinical evaluation, imaging and histopathological assessment. If an underlying cancer ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...

The FDA’s Oncologic Drugs Advisory Committee recently voted to narrow the label for checkpoint inhibitors Keytruda and Opdivo ...

Operator Welcome to BioNTech's fourth quarter and full year 2024 earnings call. I would like to hand the call over to Michael ...

Forward steps are being made in HNSCC, and the first patient with MDS has been treated with iadademstat/azacitidine.

Immunotherapy advances in triple-negative breast cancer drive personalized treatments with immune checkpoint inhibitors, aiding subtype identification and new combination therapy developments.

The full audited consolidated financial statements as of and for the year ended December 31, 2024, can be found in BioNTech's Annual Report on Form 20-F filed today with the United States Securities ...

2 The expansion phase will evaluate the agent as second- and third-line therapy for patients with recurrent/metastatic HNSCC who have received prior platinum and PD-1 inhibitor therapy ... hormone ...

The MATTERHORN Phase III trial has demonstrated that a perioperative regimen combining AstraZeneca’s Imfinzi (durvalumab) with FLOT chemotherap ...